In conclusion, despite encouraging evidence, more work is required to fully unravel the effects of IR engagement on pDC functions in specific tumor microenvironments and to uncover the beneficial role of therapeutic blockade of pDC-specific IRs in future immunotherapeutic strategies. The gene discussed is PDC; the disease is neoplasm.